Navigation Links
Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years
Date:8/5/2008

Long-Term Clinical Study Confirms Effectiveness of Autologous Therapy

DUSSELDORF, Germany, August 5 /PRNewswire/ -- The results of a two-year representative study of knee osteoarthritis, published in the internationally renowned journal "Osteoarthritis and Cartilage", confirm the safety and effectiveness of Orthokine therapy, in which anti-inflammatory proteins obtained from the patient's own blood are injected into the arthritic joint.

Researchers at Heinrich Heine University in Dusseldorf compared three treatments to determine which one produces the best long-term results for treatment of knee osteoarthritis. A total of 310 patients received a series of injections one of Orthokine, hyaluronic acid (a joint lubricant), or a placebo (table salt solution). Because of the chronic nature of arthritis, long-term treatment effects are particularly important for sufferers.

Two years after the initial treatment, 188 of the 310 patients were still experiencing reduced pain and improved function of the affected joint. The Orthokine group had the fewest patients who went on to seek further treatment. Patients who received Orthokine treatment had the greatest improvements in VAS and WOMAC scores. For the WOMAC test in particular, the outcomes were as follows: Starting from an initial WOMAC score of 124, the Orthokine group saw a reduction to a score of 58, while the final WOMAC scores for the other two groups remained well above that at 88 and 84. "This study shows that Orthokine treatment is a safe alternative to conventional methods", says study physician Carsten Moser.

"Osteoarthritis and Cartilage" is a respected scientific journal (impact factor 4.017) that publishes only original, peer-reviewed research into new methods for the treatment of diseases of the locomotor system.

Further information:

Orthogen AG

Frau Daniele Voss

Graf-Adolf-Str. 41

40210 Dusseldorf

Tel.: +49(0)211-60-255-35

Fax: +49(0)211-38700-10

E-mail: Daniele.voss@orthogen.com


'/>"/>
SOURCE Orthogen AG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... North Carolina , 12 februari 2016 ... Inc. (AAI/CML), een toonaangevende leverancier van productie ... en biotechnologische industrieën, kondigt vandaag een uitbreiding ... mogelijkheden op haar locatie in ... vraag heeft geleid tot meerdere recente investeringen. ...
(Date:2/12/2016)... 2016 --> ... Inflammation Global Clinical Trials Review, H2, 2015 provides ... clinical trials landscape along with top level data ... (G7 & E7), Trial Status, Trial Phase, Sponsor ... companies involved and enlists all trials (Trial title, ...
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... According to an ... beginning to account for a significant portion of hernia repairs throughout the United States. ... Beverly Hills Hernia Center notes that this trend has not only been expected, but ...
(Date:2/12/2016)... ... ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. ... “Those who don’t learn from history are doomed to repeat it.” , An analysis of ... year. But that takes time. , Take a close look at the warning letters ...
(Date:2/12/2016)... ... 2016 , ... T.E.N., a technology and information security executive ... Awards 2016. Finalists and winners of the ISE® Awards for both Executive and ... Gala on March 15, 2016 at the Westin Peachtree Plaza, Atlanta. , ...
(Date:2/12/2016)... ... , ... AssureVest Insurance Group, a locally owned insurance firm with offices serving ... funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd and 3rd grade ... a low-income area and has more than 60 2nd and 3rd graders with learning ...
(Date:2/12/2016)... San Ramon, CA (PRWEB) , ... February 12, 2016 , ... ... tissue donation in northern California and Nevada, announced a partnership with San Ramon Regional ... be transferred to the hospital’s facilities as a way to accommodate a more certain ...
Breaking Medicine News(10 mins):